Skip to main content

Want a detailed portfolio tracker?

IMNN
NASDAQ
$2.14

Imunon Inc (IMNN)

Imunon Inc. is a clinical-stage biotechnology company specializing in the development of innovative immune-mediated therapies for cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune responses that promote effective tumor eradication. With a diverse pipeline of therapeutics undergoing various stages of clinical evaluation and established strategic collaborations, the company is poised to make significant contributions to the field of immunotherapy, potentially transforming patient outcomes and solidifying its competitive position within the biopharmaceutical landscape.
Website: https://imunon.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Strong Buy
Target: $17.60 (+722.43%)

Market Cap

$9.02M

Price Chart

Valuation
Market Cap$9.02M
Forward P/E16.78
PEG5.03
P/S17.94
P/B5.16
Profitability
Total Revenue (TTM)$170K
Gross Profit (TTM)$2.72M
EBITDA-$15M
EPS-$4.57
Growth & Risk
EPS 5Y CAGR-46.50%
Revenue 5Y CAGR-19.37%
FCF 5Y CAGR-0.60%
Sharpe Ratio-3.01